GlobeNewswire: Endologix Contains the last 10 of 156 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:10:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/02/22/926577/0/en/Endologix-Reports-Results-for-the-Fourth-Quarter-and-Full-Year-2016.html?f=22&fvtc=4&fvtv=13240Endologix Reports Results for the Fourth Quarter and Full Year 20162017-02-22T21:05:00Z<![CDATA[IRVINE, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2016.]]>https://www.globenewswire.com/news-release/2017/02/14/917134/0/en/Endologix-Completes-Patient-Enrollment-in-the-Ovation-LUCY-Study.html?f=22&fvtc=4&fvtv=13240Endologix Completes Patient Enrollment in the Ovation® LUCY Study2017-02-14T21:01:00Z<![CDATA[First Prospective Study Evaluating EVAR in a Female Population First Prospective Study Evaluating EVAR in a Female Population]]>https://www.globenewswire.com/news-release/2017/02/07/914679/0/en/Endologix-to-Report-Fourth-Quarter-and-Full-Year-2016-Financial-Results-on-February-22-2017.html?f=22&fvtc=4&fvtv=13240Endologix to Report Fourth Quarter and Full Year 2016 Financial Results on February 22, 20172017-02-07T14:00:00Z<![CDATA[IRVINE, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2016 financial results, which will take place on Wednesday, February 22, 2017 after the close of the market.]]>https://www.globenewswire.com/news-release/2017/02/06/914249/0/en/Endologix-Announces-Appointment-of-Dan-Lemaitre-as-Chairman-of-the-Board.html?f=22&fvtc=4&fvtv=13240Endologix Announces Appointment of Dan Lemaitre as Chairman of the Board2017-02-06T14:00:00Z<![CDATA[John McDermott to Continue as Chief Executive Officer]]>https://www.globenewswire.com/news-release/2017/02/03/913989/0/en/Endologix-to-Present-at-Leerink-Partners-6th-Annual-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=13240Endologix to Present at Leerink Partners 6th Annual Global Healthcare Conference2017-02-03T21:05:00Z<![CDATA[IRVINE, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that Vaseem Mahboob, Chief Financial Officer, is scheduled to present at Leerink Partners 6th Annual Global Healthcare Conference in New York, NY. The Leerink Conference will utilize a fireside chat format for the presentation.]]>https://www.globenewswire.com/news-release/2017/01/25/910855/0/en/Endologix-Announces-Reinstatement-of-CE-Mark-for-AFX-and-AFX2-Endovascular-AAA-Systems.html?f=22&fvtc=4&fvtv=13240Endologix Announces Reinstatement of CE Mark for AFX® and AFX2 Endovascular AAA Systems2017-01-25T17:00:00Z<![CDATA[IRVINE, Calif., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced that it received notice from its Notified Body in the European Union that the CE Mark for the AFX® and AFX2 Endovascular AAA Systems has been reinstated, effective immediately. ]]>https://www.globenewswire.com/news-release/2017/01/25/910771/0/en/Positive-Three-Year-Results-from-the-Ovation-European-Post-Market-Registry-Presented-at-2017-LINC-Symposium.html?f=22&fvtc=4&fvtv=13240Positive Three-Year Results from the Ovation® European Post Market Registry Presented at 2017 LINC Symposium2017-01-25T14:00:00Z<![CDATA[IRVINE, Calif., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the presentation of positive 3-year clinical data from the Ovation European Post Market Registry at the 2017 Leipzig Interventional Course (LINC Symposium) in Leipzig, Germany.  The results were presented by Patrick Peeters, MD, Chief, Department of Cardiovascular Surgery, Imelda Hospital, Bonheiden, Belgium and investigator for the study.]]>https://www.globenewswire.com/news-release/2017/01/17/906348/0/en/Endologix-Resumes-Shipments-of-All-Sizes-of-AFX-2-Endovascular-AAA-Systems.html?f=22&fvtc=4&fvtv=13240Endologix Resumes Shipments of All Sizes of AFX®2 Endovascular AAA Systems2017-01-17T15:28:44Z<![CDATA[Appoints Laura Nagel as Vice President, Global Quality Appoints Laura Nagel as Vice President, Global Quality]]>https://www.globenewswire.com/news-release/2017/01/03/902963/0/en/Endologix-to-Present-at-the-35th-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=13240Endologix to Present at the 35th Annual J.P. Morgan Healthcare Conference2017-01-03T21:01:00Z<![CDATA[IRVINE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.]]>https://www.globenewswire.com/news-release/2016/12/30/902319/0/en/Endologix-Provides-Physicians-with-Updated-Information-about-the-AFX-Endovascular-AAA-System.html?f=22&fvtc=4&fvtv=13240Endologix Provides Physicians with Updated Information about the AFX® Endovascular AAA System2016-12-30T13:00:00Z<![CDATA[IRVINE, Calif., Dec. 30, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today issued a letter to physicians with updated information about the AFX® Endovascular AAA System.]]>